Economic burden of radical cystectomy and trimodal therapy for bladder cancer in the United States: Real-world study.
Stephen B. Williams,Halit O. Yapici,Puneet K. Singhal,Ian Weimer,Farah Pathan,Kunal Lodaya,Haojie Li
DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.555
IF: 45.3
2024-01-31
Journal of Clinical Oncology
Abstract:555 Background: Bladder cancer (BC) is exponentially deadly once it invades muscle, with the highest per patient treatment costs among cancers. Radical cystectomy (RC) and trimodal therapy (TMT) are recommended treatment options for muscle-invasive BC. This study describes patient/treatment characteristics and short- and long-term costs/healthcare utilization (HCU) associated with RC and TMT. Methods: Patients with BC undergoing RC or TMT were identified using Optum claims data (October 2015-April 2023). Incident cases were captured, and individuals diagnosed with a prior BC, secondary bladder neoplasm, and non-bladder malignancies were excluded. Costs and HCU (e.g., inpatient, outpatient, emergency, pharmacy) were evaluated up to 5 years of follow-up. Results: Median [IQR] ages of the RC (N=839) and TMT (N=484) cohorts were 71 [66-76] and 75 [69-81] years, and NCI comorbidity index was 0.50±0.43 and 0.52±0.45, respectively. Median follow-up durations were 30 [19,47] and 32 [20,48] months for RC and TMT patients, respectively. Median cost and HCU per patient in the RC cohort were 55,878- 103,579 [ 158,489] with 56 [39-86] visits in 12 months and increased to 138,597- 34,612 [ 64,263] with 19 [12-33] visits in 3 months, 65,300- 274,462 [ 421,534] with 186 [144-238] visits in 60 months (N=72). Outpatient care was the highest cost contributor for both cohorts across all time periods, except the first 3 months for RC, where inpatient care was predominant. Approximately 25% (N= 211) of patients received neoadjuvant chemotherapy before RC. For patients receiving TMT, median radiotherapy fractions delivered was 36 [18-43], and 8.1% underwent salvage RC. Conclusions: The burden of RC or TMT-treated BC patients remains high, suggesting key targets for cost containment to optimize value-based care. However, our costs are lower compared to previous literature, possibly due to 3 rd party payer (i.e., closed networks), treatment advancements, and patient selection. Future research should evaluate the cost and HCU implications of guideline-recommended treatments i.e., neoadjuvant chemotherapy followed by RC vs. TMT with advised chemotherapy type/duration for both. [Table: see text]
oncology